<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03649880</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00016043</org_study_id>
    <secondary_id>NCI-2018-01479</secondary_id>
    <secondary_id>STUDY00016043</secondary_id>
    <secondary_id>K08CA237809</secondary_id>
    <nct_id>NCT03649880</nct_id>
  </id_info>
  <brief_title>Feasibility of FMISO in Brain Tumors</brief_title>
  <official_title>Feasibility of [¹⁸F]-Fluoromisonidazole (FMISO) in Assessment of Malignant Brain Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>OHSU Knight Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well ¹⁸F- fluoromisonidazole (FMISO) works with positron&#xD;
      emission tomography (PET)/magnetic resonance imaging (MRI) in assessing participants with&#xD;
      malignant (cancerous) brain tumors. FMISO provides information about the oxygen levels in a&#xD;
      tumor, which may affect how the tumor behaves. PET/MRI imaging produces images of the brain&#xD;
      and how the body functions. FMISO PET/MRI may help investigators see how much oxygen is&#xD;
      getting in the brain tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the feasibility of obtaining FMISO PET (hypoxic volume and tumor to blood&#xD;
      background values [T/B]) and dynamic susceptibility contrast enhanced (DSC) &amp;&#xD;
      diffusion-weighted imaging (DWI) MRI measures in patients with intracranial brain tumors.&#xD;
&#xD;
      II. Determine if MRI contrast-enhancement and hypoxic volume are imaging profiles of&#xD;
      glioblastoma immunotherapy-mediated pseudoprogression or true progression in a clinical&#xD;
      trial.&#xD;
&#xD;
      SECONDARY OBJECTIVE:&#xD;
&#xD;
      I. Determine the feasibility of baseline and follow-up FMISO PET and MR imaging&#xD;
      co-registration.&#xD;
&#xD;
      TERTIARY OBJECTIVE:&#xD;
&#xD;
      I. Determine the reproducibility of the baseline FMISO PET imaging metrics as assessed by&#xD;
      baseline &quot;test&quot; and &quot;retest&quot; experiments.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Participants receive ¹⁸F-fluoromisonidazole intravenously (IV) and 1.5 - 2 hours later&#xD;
      undergo PET/CT or PET/MRI over 20-40 minutes and a retest examination within 7 days.&#xD;
      Participants may undergo 2 more PET/MRI scans no sooner than every 4 weeks.&#xD;
&#xD;
      After conclusion of the diagnostic tests, participants are followed for up to 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">February 28, 2025</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Macro-imaging level feasibility</measure>
    <time_frame>One day of diagnostic imaging</time_frame>
    <description>Will be assessed as a factor of generating quantitative positron emission tomography (PET)/magnetic resonance imaging (MRI) metrics (intra-tumoral FMISO tumor to blood [T/B] level, hypoxic volume, dynamic susceptibility contrast enhanced [DSC], and diffusion-weighted imaging [DWI] values). Following completion of cohort enrollment, the generation of each quantitative PET/MRI metric will be independently scored as a dichotomous variable; successful or non-successful. Proportional assessment will be performed to assess for project feasibility. The successful generation of quantitative PET/MRI metrics in 85% of the initial cohort of patients successfully imaged for research purposes will need to be achieved for the imaging modality to be deemed feasible for the purposes of this study. The estimated proportion of success rate for each metric along with the corresponding 95% binomial confidence interval will be provided.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MRI contrast enhancement</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Measured by Response assessment in neuro-oncology criteria sum product diameter assessment. The primary outcomes for this aim are enhancement mismatch ratio and hypoxic volume. Differences in imaging metrics will be evaluated using two sample t-test. If normal assumption is not satisfied, data transformation, or 95% confidence intervals based on bootstrapping method will be used. Exploratory analysis will assess diagnostic performance of imaging metrics (mismatch ratio and hypoxic volume) to identify pseudoprogression at earlier imaging dates.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical feasibility of PET/MRI</measure>
    <time_frame>Baseline to the start of long-term follow-up (up to 5 years)</time_frame>
    <description>The generation of co-registered imaging data sets will be independently scored as a dichotomous variable; successful or non-successful (&lt; 10mm versus [vs.] &gt; 10mm alignment error). Proportional assessment will be performed to assess for project feasibility. The estimated proportion along with the corresponding 95% binomial confidence interval will be provided.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Tumor regions</measure>
    <time_frame>Baseline to the start of long-term follow-up (up to 5 years)</time_frame>
    <description>A Wilcoxon signed rank test will be used to test the hypothesis that ¹⁸F-Fluoromisonidazole (FMISO) values observed within the T2/fluid attenuated inversion recovery (FLAIR) hyperintense region of the tumor following therapy will undergo a statistically significant change when compared to baseline pre-therapeutic values.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Malignant Brain Neoplasm</condition>
  <arm_group>
    <arm_group_label>Diagnostic (FMISO, PET/MRI or PET/CT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive ¹⁸F-fluoromisonidazole IV and 1.5 - 2 hours later undergo PET (Positron Emission Tomography) /CT (Computed Tomography) or PET/MRI (Magnetic Resonance Imaging) over 20-40 minutes and a retest examination within 7 days. Participants may undergo 2 more PET/MRI scans no sooner than every 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>¹⁸F-Fluoromisonidazole</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Diagnostic (FMISO, PET/MRI or PET/CT)</arm_group_label>
    <other_name>¹⁸F-MISO</other_name>
    <other_name>¹⁸F-Misonidazole</other_name>
    <other_name>FMISO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo PET/CT</description>
    <arm_group_label>Diagnostic (FMISO, PET/MRI or PET/CT)</arm_group_label>
    <other_name>CAT</other_name>
    <other_name>CAT Scan</other_name>
    <other_name>Computerized Axial Tomography</other_name>
    <other_name>Computerized Tomography</other_name>
    <other_name>CT</other_name>
    <other_name>CT Scan</other_name>
    <other_name>tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Magnetic Resonance Imaging</intervention_name>
    <description>Undergo PET/MRI</description>
    <arm_group_label>Diagnostic (FMISO, PET/MRI or PET/CT)</arm_group_label>
    <other_name>Magnetic Resonance Imaging Scan</other_name>
    <other_name>Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance</other_name>
    <other_name>MR Imaging</other_name>
    <other_name>MRI</other_name>
    <other_name>MRI Scan</other_name>
    <other_name>NMR Imaging</other_name>
    <other_name>NMRI</other_name>
    <other_name>Nuclear Magnetic Resonance Imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo PET/MRI</description>
    <arm_group_label>Diagnostic (FMISO, PET/MRI or PET/CT)</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET Scan</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients with a known or suspected intracranial tumor.&#xD;
&#xD;
          -  Able to provide informed written consent and/or acceptable surrogate capable of&#xD;
             providing consent on the patient's behalf.&#xD;
&#xD;
          -  Legally authorized representative (LAR)-signed informed consent and assent obtained&#xD;
             for those subjects identified as decisionally impaired&#xD;
&#xD;
          -  Intracranial lesion known or suspected to be neoplastic greater than 10 mL as assessed&#xD;
             by T2/fluid attenuated inversion recovery (FLAIR) MR imaging.&#xD;
&#xD;
          -  Karnofsky performance score &gt; 60 or Eastern Cooperative Oncology Group (ECOG) &lt; 3 as&#xD;
             assessed by referring clinician.&#xD;
&#xD;
          -  Planning to undergo or previously received therapeutic intervention for the&#xD;
             intracranial tumor.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breast feeding.&#xD;
&#xD;
          -  Contraindication to PET, MRI, FMISO, or intravenous gadolinium based contrast agents.&#xD;
&#xD;
               -  Claustrophobia.&#xD;
&#xD;
               -  Weight greater than modality maximum capacity.&#xD;
&#xD;
               -  Presence of metallic foreign body or implanted medical devices in body not&#xD;
                  documented as MRI safe according to the Oregon Health &amp; Science University (OHSU)&#xD;
                  Department of Radiology guidelines (including but not limited to cardiac&#xD;
                  pacemaker, aneurysm clips, surgical clips, prostheses, artificial hearts, valves&#xD;
                  with steel parts, metal fragments, shrapnel, tattoos near the eye, or steel&#xD;
                  implants).&#xD;
&#xD;
               -  Sickle cell disease.&#xD;
&#xD;
               -  Reduced renal function, as determined by glomerular filtration rate (GFR) &lt; 45&#xD;
                  mL/min/1.73 m^2 based on a serum creatinine level obtained per OHSU Department of&#xD;
                  Radiology and Advanced Imaging Research Center (AIRC) clinical criteria.&#xD;
&#xD;
               -  History of allergic reactions attributed to compounds of similar chemical or&#xD;
                  biologic composition to FMISO. An allergic reaction to nitroimidazoles is highly&#xD;
                  unlikely.&#xD;
&#xD;
               -  Unsure of pregnancy status as assessed by Department of Radiology and AIRC&#xD;
                  guidelines.&#xD;
&#xD;
          -  Presence of any other co-existing condition that, in the judgment of the principal&#xD;
             investigator, might increase the risk to the subject.&#xD;
&#xD;
          -  Poor peripheral intravenous access evaluated by patient history.&#xD;
&#xD;
          -  Presence of other serious systemic illnesses, including: uncontrolled infection, other&#xD;
             uncontrolled malignancy, uncontrolled diabetes type II, or psychiatric/social&#xD;
             situations which might impact the endpoint of the study or limit compliance with study&#xD;
             requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ramon Barajas</last_name>
    <role>Principal Investigator</role>
    <affiliation>OHSU Knight Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OHSU Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramon Barajas</last_name>
      <phone>503-494-3408</phone>
      <email>RADResearch@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Ramon Barajas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 6, 2018</study_first_submitted>
  <study_first_submitted_qc>August 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2018</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>OHSU Knight Cancer Institute</investigator_affiliation>
    <investigator_full_name>Ramon Barajas</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misonidazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

